Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.62
KERX's Cash to Debt is ranked lower than
84% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. KERX: 0.62 )
Ranked among companies with meaningful Cash to Debt only.
KERX' s Cash to Debt Range Over the Past 10 Years
Min: 0.62  Med: No Debt Max: No Debt
Current: 0.62
Equity to Asset 0.28
KERX's Equity to Asset is ranked lower than
83% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. KERX: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
KERX' s Equity to Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.83 Max: 0.93
Current: 0.28
-0.06
0.93
F-Score: 4
Z-Score: -4.37
M-Score: 0.13
WACC vs ROIC
24.03%
-340.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -395.75
KERX's Operating margin (%) is ranked lower than
68% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. KERX: -395.75 )
Ranked among companies with meaningful Operating margin (%) only.
KERX' s Operating margin (%) Range Over the Past 10 Years
Min: -15010.67  Med: -919.71 Max: 38.97
Current: -395.75
-15010.67
38.97
Net-margin (%) -590.50
KERX's Net-margin (%) is ranked lower than
72% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. KERX: -590.50 )
Ranked among companies with meaningful Net-margin (%) only.
KERX' s Net-margin (%) Range Over the Past 10 Years
Min: -13813.48  Med: -965.19 Max: 41.62
Current: -590.5
-13813.48
41.62
ROE (%) -165.96
KERX's ROE (%) is ranked lower than
90% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. KERX: -165.96 )
Ranked among companies with meaningful ROE (%) only.
KERX' s ROE (%) Range Over the Past 10 Years
Min: -246.34  Med: -108.23 Max: 68.51
Current: -165.96
-246.34
68.51
ROA (%) -74.70
KERX's ROA (%) is ranked lower than
81% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. KERX: -74.70 )
Ranked among companies with meaningful ROA (%) only.
KERX' s ROA (%) Range Over the Past 10 Years
Min: -135.67  Med: -73.82 Max: 31.09
Current: -74.7
-135.67
31.09
ROC (Joel Greenblatt) (%) -266.32
KERX's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. KERX: -266.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KERX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -46369.35  Med: -7601.85 Max: 7114.49
Current: -266.32
-46369.35
7114.49
EBITDA Growth (3Y)(%) 41.40
KERX's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. KERX: 41.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KERX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.1  Med: 17.4 Max: 70.9
Current: 41.4
-45.1
70.9
EPS Growth (3Y)(%) 49.80
KERX's EPS Growth (3Y)(%) is ranked higher than
91% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. KERX: 49.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KERX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.7  Med: 17.1 Max: 60.5
Current: 49.8
-44.7
60.5
» KERX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

KERX Guru Trades in Q3 2015

David Abrams 5,000,000 sh (New)
Paul Tudor Jones 14,068 sh (New)
Seth Klarman 25,791,678 sh (unchged)
Jim Simons Sold Out
» More
Q4 2015

KERX Guru Trades in Q4 2015

Chuck Royce 341,725 sh (New)
Paul Tudor Jones 44,597 sh (+217.01%)
David Abrams 5,500,000 sh (+10.00%)
Seth Klarman 25,791,678 sh (unchged)
» More
Q1 2016

KERX Guru Trades in Q1 2016

Joel Greenblatt 25,457 sh (New)
Chuck Royce 451,725 sh (+32.19%)
David Abrams 5,719,176 sh (+3.99%)
Seth Klarman 25,791,678 sh (unchged)
Paul Tudor Jones 30,106 sh (-32.49%)
» More
Q2 2016

KERX Guru Trades in Q2 2016

Joel Greenblatt 77,976 sh (+206.30%)
Paul Tudor Jones 30,687 sh (+1.93%)
Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Chuck Royce 451,725 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:OTIC, NAS:CYTK, NAS:ARDX, NAS:PDLI, OTCPK:PTCHF, NAS:ARRY, NAS:BLCM, NAS:ADAP, NAS:PGNX, NAS:ACRS, NAS:CXRX, NAS:XNPT, NAS:SPPI, NAS:EPZM, NAS:ASND, NAS:MCRB, NAS:GERN, NAS:RETA, NAS:AGEN, OTCPK:ZLDPF » details
Traded in other countries:KYX.Germany,
Keryx Biopharmaceuticals Inc is a biopharmaceutical company focused on therapies for patients with renal disease. Its first product is the AuryxiaTM (ferric citrate), an oral, absorbable iron-based compound.

Keryx Biopharmaceuticals Inc was incorporated in Delaware in October 1998. It is a biopharmaceutical company focused on therapies for patients with renal disease. Its product AuryxiaTM, also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound approved for the control of serum phosphorus levels in patients with CKD on dialysis.

Ratios

vs
industry
vs
history
P/B 7.66
KERX's P/B is ranked lower than
77% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. KERX: 7.66 )
Ranked among companies with meaningful P/B only.
KERX' s P/B Range Over the Past 10 Years
Min: 1.9  Med: 6.75 Max: 70
Current: 7.66
1.9
70
P/S 17.35
KERX's P/S is ranked lower than
63% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. KERX: 17.35 )
Ranked among companies with meaningful P/S only.
KERX' s P/S Range Over the Past 10 Years
Min: 1.18  Med: 68.1 Max: 2228
Current: 17.35
1.18
2228
Current Ratio 8.66
KERX's Current Ratio is ranked higher than
73% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. KERX: 8.66 )
Ranked among companies with meaningful Current Ratio only.
KERX' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 7.27 Max: 106.93
Current: 8.66
1.88
106.93
Quick Ratio 6.97
KERX's Quick Ratio is ranked higher than
67% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. KERX: 6.97 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 7.02 Max: 106.93
Current: 6.97
1.88
106.93
Days Inventory 1.00
KERX's Days Inventory is ranked higher than
99% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 132.42 vs. KERX: 1.00 )
Ranked among companies with meaningful Days Inventory only.
KERX' s Days Inventory Range Over the Past 10 Years
Min: 1  Med: 2126.15 Max: 2886.82
Current: 1
1
2886.82
Days Sales Outstanding 71.32
KERX's Days Sales Outstanding is ranked lower than
57% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. KERX: 71.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.51  Med: 28.12 Max: 1399.85
Current: 71.32
0.51
1399.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.50
KERX's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. KERX: -13.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KERX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.8  Med: -12.1 Max: -6.3
Current: -13.5
-34.8
-6.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 108.00
KERX's Price/Net Cash is ranked lower than
97% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. KERX: 108.00 )
Ranked among companies with meaningful Price/Net Cash only.
KERX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.09  Med: 7.49 Max: 165.5
Current: 108
1.09
165.5
Price/Net Current Asset Value 9.00
KERX's Price/Net Current Asset Value is ranked lower than
67% of the 618 Companies
in the Global Biotechnology industry.

( Industry Median: 5.45 vs. KERX: 9.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KERX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.07  Med: 7.2 Max: 26.2
Current: 9
1.07
26.2
Price/Tangible Book 8.00
KERX's Price/Tangible Book is ranked lower than
72% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. KERX: 8.00 )
Ranked among companies with meaningful Price/Tangible Book only.
KERX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.93  Med: 6.39 Max: 25.94
Current: 8
0.93
25.94
Price/Median PS Value 0.25
KERX's Price/Median PS Value is ranked higher than
90% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. KERX: 0.25 )
Ranked among companies with meaningful Price/Median PS Value only.
KERX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 1.72 Max: 76.4
Current: 0.25
0.02
76.4
Earnings Yield (Greenblatt) (%) -18.86
KERX's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. KERX: -18.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KERX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -18.93  Med: 176.85 Max: 27616.5
Current: -18.86
-18.93
27616.5

More Statistics

Revenue (TTM) (Mil) $26.10
EPS (TTM) $ -1.46
Beta2.98
Short Percentage of Float22.01%
52-Week Range $2.80 - 7.80
Shares Outstanding (Mil)105.90

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 27 59 149
EPS ($) -1.19 -0.34 0.23
EPS w/o NRI ($) -1.19 -0.34 0.23
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:KERX

Headlines

Articles On GuruFocus.com
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016 
Seth Klarman Blames Market, Investments for Rare Down Year Jan 25 2016 
David Abrams Buys Stake in Heavy Equipment Company Dec 15 2015 
Why Seth Klarman Keeps Buying Keryx Biopharma Nov 03 2015 
Seth Klarman Raises Position in Keryx Biopharmaceuticals Oct 21 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Is Seth Klarman right about Keryx Inc.? Jun 25 2015 
Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics Inc, May 15 2015 
Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data May 05 2015 

More From Other Websites
Weakness Seen in Keryx Biopharmaceuticals (KERX) Estimates: Should You Stay Away? Aug 29 2016
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx... Aug 29 2016
KERYX SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds... Aug 26 2016
Keryx Biopharmaceuticals, Inc. Sued By Block & Leviton For Violations Of The Federal Securities Laws Aug 26 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx... Aug 26 2016
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx... Aug 26 2016
KERX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Aug 26 2016
EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx... Aug 26 2016
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Aug 25 2016
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx... Aug 23 2016
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Aug 23 2016
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx... Aug 22 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of a... Aug 22 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx... Aug 19 2016
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx... Aug 19 2016
Robbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a... Aug 19 2016
ETF’s with exposure to Keryx Biopharmaceuticals, Inc. : August 18, 2016 Aug 18 2016
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx... Aug 18 2016
5 Breakout Stocks Under $10 Set to Soar Aug 18 2016
Hagens Berman Reminds Investors in Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) of October 3, 2016... Aug 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)